Skip to main content
. Author manuscript; available in PMC: 2019 May 9.
Published in final edited form as: ACS Nano. 2018 Jun 4;12(7):6563–6576. doi: 10.1021/acsnano.8b01308

Figure 8. Trimethoprim Mediated Dissociation of CSAN Therapy In Vivo.

Figure 8.

Three groups of NSG Mice (n=5) previously engrafted with MCF-7 tumors were treated with either PBS, 20 million unstimulated PBMCs or 20 million unstimulated PBMCs functionalized with 50nM αEpCAM/αCD3 CSANs by IV. One day following therapy the experimental group receiving trimethoprim/sulfamethoxazole (TMP) was dosed with 2 mg/kg of TMP. Each day their levels of IFN-γ (A), IL-2 (B), IL-6 (C) and TNF-α (D) was quantified (n=5). *P<0.05 with respect to readings that were statistically significant from bispecific PAR therapy, by 2-tailed Student’s t test.